Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin in Transformed CD20+ B-Cell Non-Hodgkin's Lymphoma
NCT00062114Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2004
- Primary completion
- Apr 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan, sponsored by Cancer and Leukemia Group B. Primary endpoints: Overall Response Rate up to 4 years and Duration of Response up to 4 years. Started Apr 2004; status: completed.
02
Drugs
ibritumomab tiuxetan
Beyond the preview
Go deeper on NCT00062114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062114.